Rett syndrome is a rare neurological disorder that affects mostly girls. The disorder affects the development of the brain. The disorder is divided into four stages: stage I: early onset; stage II: rapid destruction; stage III: plateau; and stage IV: late motor deterioration. In the first stage of Rett syndrome, the mental growth of the child stops; the child in this stage may show less eye contact. The stage II of the disorder starts between the ages of one and four years; in this stage, children usually lose the ability to perform skills. The third stage generally begins between the ages of 2 and 10 years. In this stage, children face problems with movement continue and behavior. Stage IV is the last stage of Rett syndrome and usually begins after the age of 10 years and can last for years or decades.
Common symptoms of Rett syndrome include slowed growth, unusual eye movements, agitation and irritability, problems with hand movements, poor language skills, muscles and coordination problems, and trouble with breathing. Scientists found that children with this disorder have a mutation on the X chromosome. Health care professionals diagnosed Rett syndrome on the bases of MECP2 mutation. It is a rare condition so doctors also diagnosed other condition such as prenatal brain disorder, autism spectrum disorder, metabolic disorder, and cerebral palsy to confirm Rett syndrome. Need for lifelong care and difficulty eating leading to poor nutrition, delayed growth, sleep problems are major complications of Rett syndrome. Currently, there is no cure for the disorder, but medication and therapy can help improve the symptoms. Factors such as increasing research and development as well as health care infrastructure and rising female population globally are driving the growth of the Rett syndrome treatment market. However, high medical cost might restrain the market growth in developing countries.
The global Rett syndrome treatment market is segmented based on medical treatment and region. In terms of medical treatment, the market is categorized into physical and occupational therapy, speech language therapy, medications, and others. The others segment includes behavioral therapy and nutritional therapy. Rett syndrome cannot be cured but medications can help to reduce breathing problems and abnormal heart rhythm, control seizures, and relieve indigestion and constipation.
Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37856
Geographically, the global Rett syndrome treatment market is segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market for Rett syndrome treatment market globally. In terms of revenue, the U.S. holds a major share of the North America market. The market in Europe is expanding rapidly due to high prevalence of Rett syndrome in the region. The market in Asia Pacific and Latin America is projected to expand significantly in the near future. Developing economies such as China and India are anticipated to contribute to the growth of the Asia Pacific market between 2017 and 2025 due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and rise in awareness among the people. Brazil and Mexico dominate the Latin America market for Rett syndrome treatment. South Africa, Turkey, and other developing countries in Middle East & Africa contribute to the MEA market growth.
Key players operating in the global Rett syndrome treatment market include Neuren Pharmaceuticals Ltd., Neurolixis, Anavex Life Sciences Corp., Edison Pharmaceuticals, Inc., Biohaven Pharmaceutical Holding Company Ltd., and Newron Pharmaceuticals S.p.A.